EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors



Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors



Journal of Biological Chemistry 274(45): 32478-32485



Modification of the amino terminus of regulated on activated normal T-cell expressed (RANTES) has been shown to have a significant effect on biological activity and produces proteins with antagonist properties. Two amino-terminally modified RANTES proteins, Met-RANTES and aminooxypentane-RANTES (AOP-RANTES), exhibit differential inhibitory properties on both monocyte and eosinophil chemotaxis. We have investigated their binding properties as well as their ability to activate the RANTES receptors CCR1, CCR3, and CCR5 in cell lines overexpressing these receptors. We show that Met-RANTES has weak activity in eliciting a calcium response in Chinese hamster ovary cells expressing CCR1, CCR3, and CCR5, whereas AOP-RANTES has full agonist activity on CCR5 but is less effective on CCR3 and CCR1. Their ability to induce chemotaxis of the murine pre-B lymphoma cell line, L1.2, transfected with the same receptors, consolidates these results. Monocytes have detectable mRNA for CCR1, CCR2, CCR3, CCR4, and CCR5, and they respond to the ligands for these receptors in chemotaxis but not always in calcium mobilization. AOP-RANTES does not induce calcium mobilization in circulating monocytes but is able to do so as these cells acquire the macrophage phenotype, which coincides with a concomitant up-regulation of CCR5. We have also tested the ability of both modified proteins to induce chemotaxis of freshly isolated monocytes and eosinophils. Cells from most donors do not respond, but occasionally cells from a particular donor do respond, particularly to AOP-RANTES. We therefore hypothesize that the occasional activity of AOP-RANTES to induce leukocyte chemotaxis is due to donor to donor variation of receptor expression.

(PDF emailed within 0-6 h: $19.90)

Accession: 010152120

Download citation: RISBibTeXText

PMID: 10542293

DOI: 10.1074/jbc.274.45.32478



Related references

Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. Journal of Immunology 171(10): 5498-5506, 2003

Amino-terminus modified RANTES analogues as topical virustats. Antiviral Research 51(1): 9-10, July, 2001

Promiscuity of RANTES receptors on human monocytic cells Competition for binding and desensitization of RANTES receptors by related chemotactic cytokines. Journal of Cellular Biochemistry Supplement 0(17 PART B): 83, 1993

RANTES deposition by platelets and RANTES receptors in monocyte recruitment. FASEB Journal 15(4): A328, March 7, 2001

Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. Journal of Biological Chemistry 268(8): 5834-5839, 1993

A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. Journal of Leukocyte Biology 69(6): 977-985, 2001

Effects of RANTES and MBL2 gene polymorphisms in sickle cell disease clinical outcomes: association of the g.In1.1T>C RANTES variant with protection against infections. American Journal of Hematology 84(6): 378-380, 2009

Comparative inhibition of R5 HIV infection in epidermal Langerhans cells by novel chemically modified RANTES analogues. Journal of Investigative Dermatology 117(4): 1008, October, 2001

Differential activation of CC chemokine receptors by AOP-RANTES. Journal of Biological Chemistry 275(11): 7787-7794, March 17, 2000

The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking. Cellular & Molecular Biology Letters 14(4): 537-547, 2009

Similarities and differences in RANTES- and (AOP)-RANTES- triggered signals: implications for chemotaxis. The Journal of Cell Biology 144(4): 5-65, 1999

CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Research 39(3): 175-187, 1998